diclofenac has been researched along with Stroke in 11 studies
Diclofenac: A non-steroidal anti-inflammatory agent (NSAID) with antipyretic and analgesic actions. It is primarily available as the sodium salt.
diclofenac : A monocarboxylic acid consisting of phenylacetic acid having a (2,6-dichlorophenyl)amino group at the 2-position.
Stroke: A group of pathological conditions characterized by sudden, non-convulsive loss of neurological function due to BRAIN ISCHEMIA or INTRACRANIAL HEMORRHAGES. Stroke is classified by the type of tissue NECROSIS, such as the anatomic location, vasculature involved, etiology, age of the affected individual, and hemorrhagic vs. non-hemorrhagic nature. (From Adams et al., Principles of Neurology, 6th ed, pp777-810)
| Excerpt | Relevance | Reference |
|---|---|---|
| "We observed that a low-dose diclofenac sodium infusion was effective in treating fever without systemic side effects." | 9.01 | Continuous intravenous low-dose diclofenac sodium to control a central fever after ischemic stroke in the intensive care unit: a case report and review of the literature. ( Aurilio, C; Esposito, V; Giaccari, LG; Pace, MC; Passavanti, MB; Pota, V; Sansone, P, 2019) |
| "We observed that a low-dose diclofenac sodium infusion was effective in treating fever without systemic side effects." | 5.01 | Continuous intravenous low-dose diclofenac sodium to control a central fever after ischemic stroke in the intensive care unit: a case report and review of the literature. ( Aurilio, C; Esposito, V; Giaccari, LG; Pace, MC; Passavanti, MB; Pota, V; Sansone, P, 2019) |
| "Overall, the use of NSAIDs is not associated with an increased risk of hemorrhagic stroke, although this risk was modestly significantly elevated in diclofenac and meloxicam users." | 4.93 | Nonaspirin Nonsteroidal Anti-Inflammatory Drugs and Risk of Hemorrhagic Stroke: A Systematic Review and Meta-Analysis of Observational Studies. ( Matteson, EL; Thongprayoon, C; Ungprasert, P, 2016) |
| " High-dose ibuprofen and diclofenac were associated with increased risk of ischemic stroke [hazard ratio 2·15 (95% confidence interval 1·66-2·79) and 2·37 (confidence interval 1·99-2·81), respectively]." | 3.80 | Use of nonsteroidal anti-inflammatory drugs among healthy people and specific cerebrovascular safety. ( Andersson, C; Fosbøl, EL; Gislason, GH; Kober, L; Olesen, JB; Olsen, AM; Torp-Pedersen, C, 2014) |
| "This was a post hoc analysis from the INternational VErapamil Trandolapril STudy (INVEST), which enrolled patients with hypertension and coronary artery disease." | 3.77 | Harmful effects of NSAIDs among patients with hypertension and coronary artery disease. ( Bavry, AA; Cooper-Dehoff, RM; Gong, Y; Handberg, EM; Khaliq, A; Pepine, CJ, 2011) |
| " Naproxen users had the lowest adjusted rates of serious coronary heart disease (myocardial infarction, coronary heart disease death) and serious cardiovascular disease (myocardial infarction, stroke)/death from any cause, with respective incidence rate ratios (relative to NSAID nonusers) of 0." | 3.75 | Cardiovascular risks of nonsteroidal antiinflammatory drugs in patients after hospitalization for serious coronary heart disease. ( Arbogast, PG; Castellsague, J; Chung, CP; Daugherty, JR; García-Rodríguez, LA; Murray, KT; Ray, WA; Stein, CM; Varas-Lorenzo, C, 2009) |
| "To estimate the net cardiovascular (CV) (coronary heart disease, stroke, congestive heart failure), and gastrointestinal (GI) (peptic ulcer complications) risk-benefit public health impact of the use of celecoxib compared to non-selective NSAIDs in the arthritis population." | 3.74 | Quantitative assessment of the gastrointestinal and cardiovascular risk-benefit of celecoxib compared to individual NSAIDs at the population level. ( Castellsague, J; Maguire, A; Perez-Gutthann, S; Varas-Lorenzo, C, 2007) |
| "Diclofenac initiators were compared to healthcare-seeking non-initiators and head-to-head using an approximated high dose of ≥150 mg/day vs." | 1.91 | High- vs. low-dose diclofenac and cardiovascular risks: a target trial emulation. ( Arendt-Nielsen, L; Hauge, EM; Pedersen, L; Schmidt, M; Sørensen, HT, 2023) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (27.27) | 29.6817 |
| 2010's | 6 (54.55) | 24.3611 |
| 2020's | 2 (18.18) | 2.80 |
| Authors | Studies |
|---|---|
| Schmidt, M | 1 |
| Arendt-Nielsen, L | 1 |
| Hauge, EM | 1 |
| Sørensen, HT | 1 |
| Pedersen, L | 1 |
| Giaccari, LG | 1 |
| Pace, MC | 1 |
| Passavanti, MB | 1 |
| Sansone, P | 1 |
| Esposito, V | 1 |
| Aurilio, C | 1 |
| Pota, V | 1 |
| Moore, N | 1 |
| Chen, YR | 1 |
| Hsieh, FI | 1 |
| Chang, CC | 1 |
| Chi, NF | 1 |
| Wu, HC | 1 |
| Chiou, HY | 1 |
| Bhala, N | 1 |
| Emberson, J | 1 |
| Merhi, A | 1 |
| Abramson, S | 1 |
| Arber, N | 1 |
| Baron, JA | 1 |
| Bombardier, C | 1 |
| Cannon, C | 1 |
| Farkouh, ME | 1 |
| FitzGerald, GA | 1 |
| Goss, P | 1 |
| Halls, H | 1 |
| Hawk, E | 1 |
| Hawkey, C | 1 |
| Hennekens, C | 1 |
| Hochberg, M | 1 |
| Holland, LE | 1 |
| Kearney, PM | 1 |
| Laine, L | 1 |
| Lanas, A | 1 |
| Lance, P | 1 |
| Laupacis, A | 1 |
| Oates, J | 1 |
| Patrono, C | 1 |
| Schnitzer, TJ | 1 |
| Solomon, S | 1 |
| Tugwell, P | 1 |
| Wilson, K | 1 |
| Wittes, J | 1 |
| Baigent, C | 1 |
| Ungprasert, P | 1 |
| Matteson, EL | 1 |
| Thongprayoon, C | 1 |
| Ray, WA | 1 |
| Varas-Lorenzo, C | 2 |
| Chung, CP | 1 |
| Castellsague, J | 2 |
| Murray, KT | 1 |
| Stein, CM | 1 |
| Daugherty, JR | 1 |
| Arbogast, PG | 1 |
| García-Rodríguez, LA | 1 |
| Bavry, AA | 1 |
| Khaliq, A | 1 |
| Gong, Y | 1 |
| Handberg, EM | 1 |
| Cooper-Dehoff, RM | 1 |
| Pepine, CJ | 1 |
| Fosbøl, EL | 1 |
| Olsen, AM | 1 |
| Olesen, JB | 1 |
| Andersson, C | 1 |
| Kober, L | 1 |
| Torp-Pedersen, C | 1 |
| Gislason, GH | 1 |
| Maguire, A | 1 |
| Perez-Gutthann, S | 1 |
| Pitarch Bort, G | 1 |
| de la Cuadra Oyanguren, J | 1 |
| Torrijos Aguilar, A | 1 |
| García-Melgares Linares, ML | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| WilL LOWer Dose Aspirin be More Effective Following ACS? (WILLOW-ACS)[NCT02741817] | Phase 4 | 20 participants (Actual) | Interventional | 2016-06-26 | Completed | ||
| Astaxanthin Effects on Osteoarthritis Associated Pain and Inflammatory Indicators[NCT03664466] | 0 participants (Actual) | Interventional | 2021-04-29 | Withdrawn (stopped due to Inadequate funding) | |||
| Analgesic Efficacy of Preoperative Oral Administration of Dexketoprofen Trometamol in Third Molar Surgery, Compared to Postoperative Administration[NCT02380001] | Phase 4 | 60 participants (Actual) | Interventional | 2015-01-31 | Completed | ||
| Treatment Efficacy of 'Shinbaro Capsule' in the Treatment of Hand Osteoarthritis: Randomized, Double-blinded, Placebo-controlled, Multicenter Investigator Initiated Trial.[NCT01910116] | Phase 2/Phase 3 | 220 participants (Actual) | Interventional | 2013-09-30 | Completed | ||
| Effects on Omission of NSAIDs on the Consumption of Opioids in the Standard Analgesic Regimen After Elective Laparoscopic Colorectal Cancer Resection in an ERAS Setting. A Retrospective Single-center Cohort Study.[NCT04448652] | 502 participants (Actual) | Observational [Patient Registry] | 2015-01-01 | Completed | |||
| A Phase IIa Randomized, Active-controlled, Double-blind, Dose-escalation Study in Patients With Vulvovaginal Candidiasis to Evaluate Dose Response Relationship of Clinical Efficacy, Safety and Tolerability of Topically Administered ProF-001[NCT03115073] | Phase 2/Phase 3 | 84 participants (Actual) | Interventional | 2017-04-04 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"Change in AUSCAN function score at 12 weeks from baseline = Function score at 12 weeks (0-100)- Function score at baseline (0-100). AUSCAN Function score scale ranges from 0 (no functional limitation) to 100 (worst possible functional limitation).~Negative value means improvement from baseline~Positive value means deterioration from baseline" (NCT01910116)
Timeframe: Baseline and 12 weeks
| Intervention | units on a scale (Median) |
|---|---|
| Shinbaro | -11 |
| Placebo | -2.9 |
"Change in AUSCAN function score at 16 weeks from baseline = Function score at 16 weeks (0-100)- Function score at baseline (0-100). AUSCAN Function score scale ranges from 0 (no functional limitation) to 100 (worst possible functional limitation).~Negative value means improvement from baseline~Positive value means deterioration from baseline" (NCT01910116)
Timeframe: Baseline and 16 weeks
| Intervention | units on a scale (Median) |
|---|---|
| Shinbaro | -9.9 |
| Placebo | -4.8 |
"Change in AUSCAN function score at 4 weeks from baseline = Function score at 4 weeks (0-100)- Function score at baseline (0-100). AUSCAN Function score scale ranges from 0 (no functional limitation) to 100 (worst possible functional limitation).~Negative value means improvement from baseline~Positive value means deterioration from baseline" (NCT01910116)
Timeframe: Basline and 4 weeks
| Intervention | units on a scale (Median) |
|---|---|
| Shinbaro | -6.8 |
| Placebo | -3.7 |
"Change in AUSCAN function score at 8 weeks from baseline = Function score at 8 weeks (0-100)- Function score at baseline (0-100). AUSCAN Function score scale ranges from 0 (no functional limitation) to 100 (worst possible functional limitation).~Negative value means improvement from baseline~Positive value means deterioration from baseline" (NCT01910116)
Timeframe: Baseline and 8 weeks
| Intervention | units on a scale (Median) |
|---|---|
| Shinbaro | -9.7 |
| Placebo | -4.8 |
"Change in AUSCAN pain score at 4 weeks from baseline = Pain at 4 weeks (0-100) - Pain at baseline (0-100).~AUSCAN Pain scale ranges from 0 (no pain) to 100 (worst possible pain).~Negative value means improvement from baseline~Positive value means deterioration from baseline" (NCT01910116)
Timeframe: Baseline and 4 weeks
| Intervention | units on a scale (Median) |
|---|---|
| Shinbaro | -9.0 |
| Placebo | -2.2 |
"Change in AUSCAN pain score at 12 weeks from baseline = Pain at 12 weeks (0-100)- Pain at baseline (0-100). AUSCAN Pain scale ranges from 0 (no pain) to 100 (worst possible pain).~Negative value means improvement from baseline~Positive value means deterioration from baseline" (NCT01910116)
Timeframe: Baseline, 12 weeks
| Intervention | units on a scale (Median) |
|---|---|
| Shinbaro | -14.6 |
| Placebo | -8.0 |
"Change in AUSCAN pain score at 16 weeks from baseline = Pain at 16 weeks (0-100)- Pain at baseline (0-100). AUSCAN Pain scale ranges from 0 (no pain) to 100 (worst possible pain).~Negative value means improvement from baseline~Positive value means deterioration from baseline" (NCT01910116)
Timeframe: Baseline and 16 weeks
| Intervention | units on a scale (Median) |
|---|---|
| Shinbaro | -15.6 |
| Placebo | -4.4 |
"Change in AUSCAN pain score at 8 weeks from baseline = Pain at 8 weeks (0-100)- Pain at baseline (0-100). AUSCAN Pain scale ranges from 0 (no pain) to 100 (worst possible pain).~Negative value means improvement from baseline~Positive value means deterioration from baseline" (NCT01910116)
Timeframe: Baseline, 8 weeks
| Intervention | units on a scale (Median) |
|---|---|
| Shinbaro | -13.4 |
| Placebo | -2.2 |
"Change in AUSCAN stiffness score at 12 weeks from baseline = Stiffness at 12 weeks (0-100)- Stiffness at baseline (0-100). AUSCAN Stiffness scale ranges from 0 (no stiffness) to 100 (worst possible stiffness).~Negative value means improvement from baseline~Positive value means deterioration from baseline" (NCT01910116)
Timeframe: Basline and 12 weeks
| Intervention | units on a scale (Median) |
|---|---|
| Shinbaro | -14.0 |
| Placebo | -11.0 |
"Change in AUSCAN stiffness score at 16 weeks from baseline = Stiffness at 16 weeks (0-100)- Stiffness at baseline (0-100). AUSCAN Stiffness scale ranges from 0 (no stiffness) to 100 (worst possible stiffness).~Negative value means improvement from baseline~Positive value means deterioration from baseline" (NCT01910116)
Timeframe: Baseline, 16 weeks
| Intervention | units on a scale (Median) |
|---|---|
| Shinbaro | -10.0 |
| Placebo | -8.0 |
"Change in AUSCAN stiffness score at 4 weeks from baseline = Stiffness at 4 weeks (0-100)- Stiffness at baseline (0-100). AUSCAN Stiffness scale ranges from 0 (no stiffness) to 100 (worst possible stiffness).~Negative value means improvement from baseline~Positive value means deterioration from baseline" (NCT01910116)
Timeframe: Baseline and 4 weeks
| Intervention | units on a scale (Median) |
|---|---|
| Shinbaro | -9.0 |
| Placebo | -6.0 |
"Change in AUSCAN stiffness score at 8 weeks from baseline = Stiffness at 8 weeks (0-100)- Stiffness at baseline (0-100). AUSCAN Stiffness scale ranges from 0 (no stiffness) to 100 (worst possible stiffness).~Negative value means improvement from baseline~Positive value means deterioration from baseline" (NCT01910116)
Timeframe: baseline and 8 weeks
| Intervention | units on a scale (Median) |
|---|---|
| Shinbaro | -12.0 |
| Placebo | -6 |
Number of patients who met OMERACT-OARSI criteria = significant clinical improvement in osteoarthritis symptom after treatment (NCT01910116)
Timeframe: Baselie and 16 weeks
| Intervention | participants (Number) |
|---|---|
| Shinbaro | 55 |
| Placebo | 40 |
"Change in Patient global assessment (PGA) at 12 weeks from baseline = PGA at 12 weeks (0-100)- PGA score at baseline (0-100). GPA scale ranges from 0 (excellent condition) to 100 (worst possible worse possible condition).~Negative value means improvement from baseline~Positive value means deterioration from baseline" (NCT01910116)
Timeframe: Baseline and 12 weeks
| Intervention | units on a scale (Median) |
|---|---|
| Shinbaro | -11.0 |
| Placebo | -6.0 |
"Change in Patient global assessment (PGA) at 16 weeks from baseline = PGA at 16 weeks (0-100)- PGA score at baseline (0-100). PGA scale ranges from 0 (excellent condition) to 100 (worst possible worse possible condition).~Negative value means improvement from baseline~Positive value means deterioration from baseline" (NCT01910116)
Timeframe: Baseline and 16 weeks
| Intervention | units on a scale (Median) |
|---|---|
| Shinbaro | -10.0 |
| Placebo | -8.5 |
"Change in Patient global assessment (PGA) at 4 weeks from baseline = PGA at 4 weeks (0-100)- PGA score at baseline (0-100). PGA scale ranges from 0 (excellent condition) to 100 (worst possible worse possible condition).~Negative value means improvement from baseline~Positive value means deterioration from baseline" (NCT01910116)
Timeframe: Baseline and 4 weeks
| Intervention | units on a scale (Median) |
|---|---|
| Shinbaro | -9.0 |
| Placebo | -3.0 |
"Change in Patient global assessment (PGA) at 8 weeks from baseline = PGA at 8 weeks (0-100)- PGA score at baseline (0-100). PGA scale ranges from 0 (excellent condition) to 100 (worst possible worse possible condition).~Negative value means improvement from baseline~Positive value means deterioration from baseline" (NCT01910116)
Timeframe: Baseline and 8 weeks
| Intervention | units on a scale (Median) |
|---|---|
| Shinbaro | -10.0 |
| Placebo | -6.0 |
"Change in Physician global assessment (PhGA) at 12 weeks from baseline = PhGA at 12 weeks (0-100)- PhGA score at baseline (0-100). PhGA scale ranges from 0 (excellent condition) to 100 (worst possible worse possible condition).~Negative value means improvement from baseline~Positive value means deterioration from baseline" (NCT01910116)
Timeframe: Baseline and 12 weeks
| Intervention | units on a scale (Median) |
|---|---|
| Shinbaro | -19.0 |
| Placebo | -13 |
"Change in Physician global assessment (PhGA) at 16 weeks from baseline = PhGA at 16 weeks (0-100)- PhGA score at baseline (0-100). PhGA scale ranges from 0 (excellent condition) to 100 (worst possible worse possible condition).~Negative value means improvement from baseline~Positive value means deterioration from baseline" (NCT01910116)
Timeframe: Baseline and 16 weeks
| Intervention | units on a scale (Median) |
|---|---|
| Shinbaro | -12 |
| Placebo | -6.5 |
"Change in Physician global assessment (PhGA) at 4 weeks from baseline = PhGA at 4 weeks (0-100)- PhGA score at baseline (0-100). GPA scale ranges from 0 (excellent condition) to 100 (worst possible worse possible condition).~Negative value means improvement from baseline~Positive value means deterioration from baseline" (NCT01910116)
Timeframe: baseline and 4 weeks
| Intervention | units on a scale (Median) |
|---|---|
| Shinbaro | -12 |
| Placebo | -7.0 |
"Change in Physician global assessment (PhGA) at 8 weeks from baseline = PhGA at 8 weeks (0-100)- PhGA score at baseline (0-100). PhGA scale ranges from 0 (excellent condition) to 100 (worst possible worse possible condition).~Negative value means improvement from baseline~Positive value means deterioration from baseline" (NCT01910116)
Timeframe: Baseline and 8 weeks
| Intervention | units on a scale (Median) |
|---|---|
| Shinbaro | -16.0 |
| Placebo | -11.5 |
"Change in Swollen joint count (SJC) at 12 weeks from baseline = SJC at 12 weeks - TJC at baseline..~Negative value means improvement from baseline~Positive value means deterioration from baseline" (NCT01910116)
Timeframe: Baseline and 12 weeks
| Intervention | Joints (Median) |
|---|---|
| Shinbaro | 0 |
| Placebo | 0 |
"Change in Swollen joint count (SJC) at 16 weeks from baseline = SJC at 16 weeks - TJC at baseline..~Negative value means improvement from baseline~Positive value means deterioration from baseline" (NCT01910116)
Timeframe: Baseline and 16 weeks
| Intervention | Joints (Median) |
|---|---|
| Shinbaro | 0 |
| Placebo | 0 |
"Change in Swollen joint count (SJC) at 4 weeks from baseline = SJC at 4 weeks - TJC at baseline..~Negative value means improvement from baseline~Positive value means deterioration from baseline" (NCT01910116)
Timeframe: Baseline and 4 weeks
| Intervention | Joints (Median) |
|---|---|
| Shinbaro | 0 |
| Placebo | 0 |
"Change in Swollen joint count (SJC) at 8 weeks from baseline = SJC at 8 weeks - TJC at baseline..~Negative value means improvement from baseline~Positive value means deterioration from baseline" (NCT01910116)
Timeframe: Baseline and 8 weeks
| Intervention | Joints (Median) |
|---|---|
| Shinbaro | 0 |
| Placebo | 0 |
"Change in Tender joint count (TJC) at 12 weeks from baseline = TJC at 12 weeks - TJC at baseline..~Negative value means improvement from baseline~Positive value means deterioration from baseline" (NCT01910116)
Timeframe: Baseline and 12 weeks
| Intervention | joints (Median) |
|---|---|
| Shinbaro | -2.0 |
| Placebo | -1.0 |
"Change in Tender joint count (TJC) at 16 weeks from baseline = TJC at 16 weeks - TJC at baseline..~Negative value means improvement from baseline~Positive value means deterioration from baseline" (NCT01910116)
Timeframe: Baseline and 16 weeks
| Intervention | joints (Median) |
|---|---|
| Shinbaro | -2.0 |
| Placebo | -1.0 |
"Change in Tender joint count (TJC) at 4 weeks from baseline = TJC at 4 weeks - TJC at baseline..~Negative value means improvement from baseline~Positive value means deterioration from baseline" (NCT01910116)
Timeframe: Baseline and 4 weeks
| Intervention | joints (Median) |
|---|---|
| Shinbaro | -1 |
| Placebo | 0 |
"Change in Tender joint count (TJC) at 8 weeks from baseline = TJC at 8 weeks - TJC at baseline..~Negative value means improvement from baseline~Positive value means deterioration from baseline" (NCT01910116)
Timeframe: Baseline and 8 weeks
| Intervention | Joints (Median) |
|---|---|
| Shinbaro | -1.0 |
| Placebo | -1.0 |
yes = AAP rescue use, no = no AAP rescue use (NCT01910116)
Timeframe: 12 weeks and 16 weeks
| Intervention | participants (Number) | |
|---|---|---|
| yes | no | |
| Placebo | 2 | 104 |
| Shinbaro | 4 | 105 |
yes = AAP rescue use, no = no AAP rescue use (NCT01910116)
Timeframe: 4 weeks and 8 weeks
| Intervention | participants (Number) | |
|---|---|---|
| yes | no | |
| Placebo | 7 | 99 |
| Shinbaro | 10 | 99 |
yes = AAP rescue use, no = no AAP rescue use (NCT01910116)
Timeframe: 8 weeks and 12 weeks
| Intervention | participants (Number) | |
|---|---|---|
| yes | no | |
| Placebo | 4 | 102 |
| Shinbaro | 4 | 105 |
yes = AAP rescue use, no = no AAP rescue use (NCT01910116)
Timeframe: Baseline 4 weeks
| Intervention | participants (Number) | |
|---|---|---|
| yes | no | |
| Placebo | 4 | 102 |
| Shinbaro | 7 | 102 |
Number of patients who met OMERACT-OARSI criteria = significant clinical improvement in osteoarthritis symptom after treatment (NCT01910116)
Timeframe: Baseline and 12 weeks
| Intervention | participants (Number) | |
|---|---|---|
| responder | nonresponder | |
| Placebo | 43 | 63 |
| Shinbaro | 62 | 47 |
Number of patients who met OMERACT-OARSI criteria = significant clinical improvement in osteoarthritis symptom after treatment (NCT01910116)
Timeframe: Baseline and 8 weeks
| Intervention | participants (Number) | |
|---|---|---|
| responder | nonresponder | |
| Placebo | 38 | 68 |
| Shinbaro | 56 | 53 |
Outcome Measures in Rheumatology-Osteoarthritis Research Society International (OMERACT-OARSI) Number of patients who met OMERACT-OARSI criteria = significant clinical improvement in osteoarthritis symptom after treatment (NCT01910116)
Timeframe: Baseline and 4 weeks
| Intervention | participants (Number) | |
|---|---|---|
| Responder | Nonresponder | |
| Placebo | 32 | 74 |
| Shinbaro | 48 | 61 |
4 reviews available for diclofenac and Stroke
| Article | Year |
|---|---|
Continuous intravenous low-dose diclofenac sodium to control a central fever after ischemic stroke in the intensive care unit: a case report and review of the literature.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Brain Ischemia; Diclofenac; Female; Fever; Humans; In | 2019 |
Coronary Risks Associated with Diclofenac and Other NSAIDs: An Update.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiotoxicity; Cardiovascular Diseases; Cyclooxygenase 2 I | 2020 |
Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Vessels; Coronary Disease; Cyclooxygenase 2 Inhibitor | 2013 |
Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Vessels; Coronary Disease; Cyclooxygenase 2 Inhibitor | 2013 |
Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Vessels; Coronary Disease; Cyclooxygenase 2 Inhibitor | 2013 |
Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Vessels; Coronary Disease; Cyclooxygenase 2 Inhibitor | 2013 |
Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Vessels; Coronary Disease; Cyclooxygenase 2 Inhibitor | 2013 |
Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Vessels; Coronary Disease; Cyclooxygenase 2 Inhibitor | 2013 |
Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Vessels; Coronary Disease; Cyclooxygenase 2 Inhibitor | 2013 |
Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Vessels; Coronary Disease; Cyclooxygenase 2 Inhibitor | 2013 |
Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Vessels; Coronary Disease; Cyclooxygenase 2 Inhibitor | 2013 |
Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Vessels; Coronary Disease; Cyclooxygenase 2 Inhibitor | 2013 |
Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Vessels; Coronary Disease; Cyclooxygenase 2 Inhibitor | 2013 |
Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Vessels; Coronary Disease; Cyclooxygenase 2 Inhibitor | 2013 |
Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Vessels; Coronary Disease; Cyclooxygenase 2 Inhibitor | 2013 |
Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Vessels; Coronary Disease; Cyclooxygenase 2 Inhibitor | 2013 |
Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Vessels; Coronary Disease; Cyclooxygenase 2 Inhibitor | 2013 |
Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Vessels; Coronary Disease; Cyclooxygenase 2 Inhibitor | 2013 |
Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Vessels; Coronary Disease; Cyclooxygenase 2 Inhibitor | 2013 |
Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Vessels; Coronary Disease; Cyclooxygenase 2 Inhibitor | 2013 |
Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Vessels; Coronary Disease; Cyclooxygenase 2 Inhibitor | 2013 |
Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Vessels; Coronary Disease; Cyclooxygenase 2 Inhibitor | 2013 |
Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Vessels; Coronary Disease; Cyclooxygenase 2 Inhibitor | 2013 |
Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Vessels; Coronary Disease; Cyclooxygenase 2 Inhibitor | 2013 |
Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Vessels; Coronary Disease; Cyclooxygenase 2 Inhibitor | 2013 |
Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Vessels; Coronary Disease; Cyclooxygenase 2 Inhibitor | 2013 |
Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Vessels; Coronary Disease; Cyclooxygenase 2 Inhibitor | 2013 |
Nonaspirin Nonsteroidal Anti-Inflammatory Drugs and Risk of Hemorrhagic Stroke: A Systematic Review and Meta-Analysis of Observational Studies.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cerebral Hemorrhage; Diclofenac; Humans; Ibuprof | 2016 |
7 other studies available for diclofenac and Stroke
| Article | Year |
|---|---|
High- vs. low-dose diclofenac and cardiovascular risks: a target trial emulation.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Brain Ischemia; Cardiovascular System; Diclofenac; H | 2023 |
Effect on Risk of Stroke and Acute Myocardial Infarction of Nonselective Nonsteroidal Anti-Inflammatory Drugs in Patients With Rheumatoid Arthritis.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; | 2018 |
Cardiovascular risks of nonsteroidal antiinflammatory drugs in patients after hospitalization for serious coronary heart disease.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Celecoxib; Cohort Studies; C | 2009 |
Harmful effects of NSAIDs among patients with hypertension and coronary artery disease.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antihypertensive Agents; Blood Pressure; Celec | 2011 |
Use of nonsteroidal anti-inflammatory drugs among healthy people and specific cerebrovascular safety.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Brain Ischemia; Cohort Studies; Denmark; Diclofenac; | 2014 |
Quantitative assessment of the gastrointestinal and cardiovascular risk-benefit of celecoxib compared to individual NSAIDs at the population level.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Cardiovascular D | 2007 |
Allergic contact dermatitis due to aceclofenac.
Topics: Administration, Cutaneous; Aged; Anti-Inflammatory Agents, Non-Steroidal; Dermatitis, Allergic Conta | 2006 |